Summary:
- Syntis Bio, a biopharmaceutical company based in Boston, secured $38M in Series A funding.
- The funding round was led by Cerberus Ventures and included participation from various new investors.
- The company plans to use the funds to expand its operations and research and development efforts.
Rewritten Article:
Syntis Bio, a clinical-stage biopharmaceutical company headquartered in Boston, recently announced a significant milestone by raising $38 million in Series A funding. The funding round was spearheaded by Cerberus Ventures and saw the participation of several new investors, including Mansueto Investments, Woori Venture Partners, and Apollo Labs, among others. This substantial investment will enable Syntis Bio to further expand its operations and intensify its research and development initiatives.
Under the leadership of CEO Rahul Dhanda, Syntis Bio is dedicated to developing innovative oral therapies that target a range of health conditions, including obesity, diabetes, and rare diseases. By leveraging the unique biology of the small intestine, the company aims to provide accessible, effective, and sustainable solutions for patients across various healthcare domains. One of its flagship programs, SYNT-101, focuses on combatting obesity, while its pipeline includes therapies for orphan metabolic disorders and intestinal-related ailments.
In addition to the Series A funding, Syntis Bio has also secured up to $5 million in non-dilutive funding from the National Institutes of Health (NIH) through Fast-Track Small Business Innovation Research (SBIR) awards. These awards, granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), support the advancement of the company’s SYNTâ„¢ platform, which utilizes synthetic tissue-lining technology for targeted drug delivery in the small intestine.
The strategic infusion of capital and support from investors will undoubtedly propel Syntis Bio towards achieving its mission of revolutionizing healthcare through cutting-edge oral therapies. With a focus on addressing unmet medical needs and improving patient outcomes, the company is well-positioned to make a significant impact in the biopharmaceutical industry.
FinSMEs
01/07/2025
